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Abstract
The case-cohort study design has often been used in studies of a rare disease or for a common 
disease with some biospecimens needing to be preserved for future studies. A case-cohort study 
design consists of a random sample, called the subcohort, and all or a portion of the subjects with 
the disease of interest. One advantage of the case-cohort design is that the same subcohort can be 
used for studying multiple diseases. Stratified random sampling is often used for the subcohort. 
Additive hazards models are often preferred in studies where the risk difference, instead of relative 
risk, is of main interest. Existing methods do not use the available covariate information fully. We 
propose a more efficient estimator by making full use of available covariate information for the 
additive hazards model with data from a stratified case-cohort design with rare (the traditional 
situation) and non-rare (the generalized situation) diseases. We propose an estimating equation 
approach with a new weight function. The proposed estimators are shown to be consistent and 
asymptotically normally distributed. Simulation studies show that the proposed method using all 
available information leads to efficiency gain and stratification of the subcohort improves 
efficiency when the strata are highly correlated with the covariates. Our proposed method is 
applied to data from the Atherosclerosis Risk in Communities (ARIC) study.
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1. Introduction
In large cohort studies, obtaining expensive covariate information on all members in the 
entire cohort could be costly and might not be feasible due to limited financial resource. In 
order to reduce cost, the case-cohort study design was proposed by Prentice [1]. Under the 
case-cohort design, covariate information is collected only from a random sample of the 
cohort, called the subcohort, as well as all the subjects who have the disease of interest. A 
key advantage for the case-cohort study is that the same subcohort can be used when several 
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types of diseases are of interest [2]. For example, one of the goals in the Atherosclerosis 
Risk in Communities (ARIC) study is to investigate the association between the genetic 
variation in PTGS1 and coronary heart disease (CHD) as well as stroke [3]. To preserve 
blood specimens and reduce cost, two case-cohort studies were conducted separately using 
the same subcohort.
In spite of the extensive work on multiplicative hazards models for case-cohort studies, only 
a few methods for case-cohort studies with additive hazards models have been studied. For 
univariate failure time, Kulich and Lin [4] proposed semiparametric estimation and 
developed the asymptotic properties in additive hazards models from case-cohort data. Sun 
et al. [5] extended this approach to competing risks analysis in the case-cohort study. To 
compare the risk effect on different diseases, Kang et al. [6] proposed modeling them 
simultaneously using an additive hazards model for the stratified case-cohort design. 
However, they did not fully use all the available information on the covariate of interest. For 
example, in the ARIC study, the genetic variation in PTGS1 was collected from the 
subcohort and all subjects with CHD and/or stroke. When analysis for CHD was conducted, 
the PTGS1 information collected on stroke patients outside the subcohort was disregarded. 
This could induce loss of efficiency. Recently, Kim et al. [7] proposed the weight function 
to use this extra information in multiplicative hazard models for rare diseases. Similar ideas 
on using information from cases of other types have been proposed for nested case-control 
data, for example, Salim et al. (2009) [8] and Stoer and Samuelsen (2012) [9]. However, in 
many biomedical studies with common diseases, due to financial restrictions as well as for 
reserving biospecimens for future use, it is more desirable to sample a portion of the cases 
instead of including all the cases in the case-cohort study. Therefore, we extend Kim et al. 
[7]’s approach to the non-rare diseases situation in additive hazards models.
In this paper, we propose more efficient estimation methods for the additive hazards model 
with data from case-cohort studies by making full use of available covariate information. 
We also take into account two important features of the sampling in the case-cohort design. 
One is stratification. Stratified sampling is commonly used in survey sampling to increase 
the representation of the sample and to improve estimation efficiency. Due to these 
advantages, stratified random sample is often used in drawing the subcohort in the case-
cohort design. The other feature is case sampling. We refer to the design that incorporates 
both features as the generalized stratified case-cohort design. We propose an estimation 
procedure for the parameters in the additive hazards model for the generalized stratified 
case-cohort design with multivariate failure times. In Section 2, we introduce the model and 
propose estimation procedures. Section 3 summarizes asymptotic properties for the proposed 
estimators and Section 4 reports simulation results to investigate the performance of the 
proposed estimators in finite samples. In Section 5, we illustrate the methods by analyzing 
data from the ARIC study. Concluding remarks are provided in Section 6.
2. Model
Suppose that a cohort study consists of n independent subjects with K diseases of interest 
and can be divided into L mutually exclusive strata based on available information V from 
all cohort members. Let Tlik and Clik denote the potential failure time and the potential 
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censoring time for disease k of subject i within stratum l, respectively. The failure time Tlik 
is assumed to be independent of Clik given covariates. Let Zlik(t) be a p × 1 possibly time-
dependent covariate vector for disease k of subject i within stratum l at time t. We assume 
that time-dependent covariates are external; that is, they are not influenced by the disease 
processes [10]. Let Xlik = min(Tlik, Clik) denote the observed time, Δlik = I(Tlik ≤ Clik) the 
indicator for failure, Nlik(t) = I(Xlik ≤ t, Δlik = 1) the counting process, and Ylik(t) = I(Xlik ≥ t) 
the at risk indicator for disease k of subject i within stratum l, where I(.) is the indicator 
function. Let Vi denote a discrete random variable for stratification of subject i. Let τ denote 
the end of study time.
Consider the following additive hazards model for Tlik given Zlik(t)
(1)
where λ0k(t) is a baseline hazard function for disease k and β0 is a p-vector of unknown 
regression parameters. Model (1) can accommodate the disease-specific effect model 
 which is a special case of model (1) with 
 and 
where 0T is a 1 × p zero vector.
Suppose that the total size n of the cohort is partitioned into groups of size nl, l = 1, …, L. 
We select a fixed number ñl of subjects from the nl subjects in stratum l for the subcohort by 
using simple random sampling. The total size of the subcohort is .
Let ξli be an indicator for subcohort membership for subject i in stratum l. Each subject in 
stratum l has the same probability α̃l = Pr(ξli = 1) = ñl/nl of being selected into the 
subcohort. The covariates Zlik(t)(0 ≤ t ≤ τ) are measured for subjects in the subcohort and 
those with any disease of interest.
Under the generalized stratified case-cohort design, after selection of the subcohort, we 
select a fixed number m̃lk of the cases of disease k among non-subcohort members with 
disease k in stratum l using simple random sampling. Denote by  the total 
number of cases of disease k outside of the subcohort. Let ηlik be an indicator for whether 
subject i in stratum l is sampled as a non-subcohort subject with disease k. Let γ̃lk = Pr (ηlik 
= 1|Δlik = 1, ξli = 0) = m̃lk/(olk − õlk) denote the selection probability of subjects among non-
subcohort members with disease k in stratum l, where olk and õlk denote the number of 
subjects with disease k in the cohort and in the subcohort within stratum l, respectively. Due 
to the sampling scheme, the elements in (ηl1k, …, ηlnlk) are correlated, however, (ηl1k, …, 
ηlnlk) is independent of (ηl′1k′, …, ηl′nl′k′) for k ≠ k′ or l ≠ l′.
2.1. Estimation
Suppose that there re  independent subjects with K diseases of interest. Let the 
independent failure time vector be Tli = (Tli1, …, Tlik) and the observed time vector be Xli = 
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(Xli1, …, Xlik,) i = 1, …, n. Thus, for subject i in stratum l, complete observations are (Xlik, 
Δlik, ξli, Zlik(t), 0 ≤ t ≤ τ, k = 1, …, K, Vi) when ξli = 1 or Δlik = 1 and (Xlik, Δlik, ξi, k = 1, …, 
K, Vi) when ξli = 0 and Δlik = 0.
Consider the situation with non-rare diseases of interest, but with covariate information for 
subjects with other diseases being available. Without using covariate information collected 
on subjects with other diseases, Kang et al. [6] considered the additive hazards model for 
generalized case-cohort designs using stratified simple random sampling. The regression 
parameter β0 in (1) can be estimated by solving the estimating equation [6]:
(2)
where
and  with 
 and 
. The time-invariant weight can 
involve fixed weights α̂lk and q̂lk with that replace α̂lk(t) and q̂lk(t) at t = 0. If we select all 
cases i.e. q̂lk(t) for all k is 1, the weight function reduces to  in 
traditional case-cohort studies.
The estimator β̂ is defined as the solution to (2) and has the following explicit form:
where a⊗2 = aaT.
To make full use of covariate information collected on subjects with other diseases, we 
proposed the following weight function πlik(t) when there are two diseases (i.e. K = 2):
(3)
where
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The proposed weight function uses extra covariate information collected on the selected 
subjects with the other disease. Specifically, subcohort subjects without either disease (i.e. 
) are weighted by α̃lk(t)−1, the inverse of the estimated selection 
probabilities, while subjects with disease 1 or disease 2 in the subcohort (i.e. 
) are weighted by 1. To use the information collected on the 
sampled subjects with disease 2, the sampled non-subcohort subjects with disease 1 (i.e. 
Δli1(1 − ξli)ηli1 = 1) can be decomposed into two groups: those with only disease 1 (i.e. 
Δli1(1 − Δli2)(1 − ξli)ηli1 = 1) and those with both disease 1 and disease 2 (i.e. Δli1Δli2(1 − 
ξli)ηli1 = 1). The sampled subjects in the first group (i.e. Δli1(1 − Δli2)(1 − ξli) = 1) are 
weighted by γ̃l1k(t)−1, the inverse of their estimated sampling probabilities. Similarly, the 
sampled non-subcohort subjects with disease 2 can also be decomposed into two groups: 
those with only disease 2 (i.e. Δli1(1 − Δli2)(1 − ξli)ηli2 =1) and those with both diseases (i.e. 
Δli1Δli2(1 − ξli)ηli2 =1). Those with only disease 2 are weighted by γ̃l2k(t)−1, the inverse of 
their estimated sampling probabilities. For those sampled non-subcohort subjects with both 
diseases, they can be weighted by , the inverse of the estimated sampling probabilities 
based on disease 1 or disease 2. Note the weight function for the traditional case-cohort 
design proposed by Kim et al. [7]  is a 
special case of the proposed weight function (3).
We consider the following weighted estimating equation:
(4)
where
The explicit form of β̃, which is defined by the solution of the estimating equation in (4), is:
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Let . A Breslow-Aalen type estimator of the baseline cumulative hazard 
function is given by Λ̃0k(β̃, t), where
(5)
3. Asymptotic properties
In this section we present the asymptotic properties of the proposed methods. Because the 
traditional case-cohort study is a special case of the generalized case-cohort study, we 
present only the results for the generalized case-cohort study. The following theorems 
summarize the main results.
Theorem 3.1—Under the regularity conditions in Web appendix, β̃ converges in 
probability to β0 and n1/2(β̃ − β0) converges in distribution to a mean zero normal 
distribution with covariance matrix , where
Note that Σ(β0) consists of three parts. The first part, , is the contribution to the 
variance from the full cohort, the second part, , is due to sampling the subcohort 
from the full cohort, and the last part, , is due to sampling a fraction of 
cases. If we select all cases, which is the traditional stratified case-cohort design, the last 
variance is zero.
We summarize the asymptotic properties of the proposed baseline cumulative hazard 
estimator Λ̃0k(β̃, t) in the following theorem.
Theorem 3.2—Under the regularity conditions in Web appendix, Λ̃0k(β̃, t) is a consistent 
estimator of Λ0k(t) in t ∈ [0, τ] k =1, 2) and G(t)={G1(t),G2(t)}T =[n1/2{Λ̃01(β̃, t) − Λ01(t)}, 
n1/2{Λ̃02(β̃, t) − Λ02(t))}]T converges weakly to the Gaussian process (t)={ (t), (t)}T in 
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D[0, τ]K with mean zero and the following covariance function (t, s) between (t) and 
(s) for j ≠ k.
where the explicit forms of μlik(β, t),wlik(β, t), and νlik(β, t) are given in Web Appendix.
The proof of Λ̃0k(β̃, t) is provided in Web appendix. The proof uses Taylor expansion, the 
Kolmogorov-Centsov theorem, weak convergence of the baseline cumulative hazard 
estimator from full cohort studies with multivariate failure time, Hájek[11]’s central limit 
theorem for finite population sampling, and the Cramer-Wold device.
4. Simulations
We conducted simulation studies to examine the performance of the proposed methods and 
to compare them with the existing methods. Correlated bivariate failure time data were 
generated from the Clayton-Cuzick model [12]. The bivariate survival function for the 
bivariate survival time (T1, T2) given (Zl1,Zl2) has the following form:
where λ0k(t) and βk are the baseline hazard function and the effect of the covariate for 
disease k, respectively, l indexes the two strata, and θ is the parameter that controls the 
correlation between the failure times for the two diseases. Smaller θ indicates higher 
correlation between the two failure times T1 and T2. The relationship between Kendall’s tau, 
τθ, and θ is . For θ, we used values of 0.10, 0.67, and 4 and the corresponding 
Kendall’s tau values are 0.83, 0.43, and 0.11, respectively. We also consider independent 
failure times (τθ =0). We set the baseline hazard function λ01 =2 for the first failure event 
type, k =1, and λ02 =4 for the second failure event type, k =2. The regression parameters 
considered were β0 =0, 0.1, 0.3, and 0.5.
We generated Z from Bernouilli distribution with pr(Z =1) = 0.5 under the situation Zl1 =Zl2 
=Z. To consider stratified subcohort sampling from two strata defined by Vi, we defined two 
parameters: η =Pr(V =1|Z =1) and ν =Pr(V =0|Z =0) where η is the sensitivity and ν the 
specificity for Z. Both η and ν greater than 0.5 indicate that V is highly correlated with Z. 
For stratified case-cohort studies, we set the values [η, ν]=[0.5, 0.5] and [0.7, 0.7]. Thus, a 
stratum variable is simulated with Pr(V =1)=(1 − ν)Pr(Z =0) + ηPr(Z =1)=0.5. Censoring 
times were generated from uniform distribution [0, u]where u depends on the specified level 
of the censoring probability.
For simulations of the traditional case-cohort design, we set event proportions of 
approximately 5% for k =1 and 9% for k =2. For the simulations of the generalized case-
cohort design, the event proportions were set as 15% for k =1 and 26% for k =2 and we 
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sampled half of the cases outsides the subcohort, [γ1, γ2]=[0.5, 0.5]. The sample size of the 
full cohort was set to be n =1000. For stratified sampling, we set the total subcohort sizes as 
100 and 200 and sampled a subcohort of size ñl =ñ ×ql from each stratum. For each 
configuration, we conducted 2000 simulations.
We first considered the traditional and generalized case-cohort design using unstratified 
sampling but with covariates available on subjects with other diseases. For generalized case-
cohort design, we sampled half of the cases outside the subcohort. We examined the 
performance of our proposed estimator and compared our results with those in Kang et al. 
(2013) [6]. We fitted disease-specific model. Table 1 summarizes the results for β1̃, β̃2, β̂1, 
and β̂2. For different combinations of regression parameter values, event proportion, study 
design, subcohort sample size, and correlation, Table 1 shows the average of the estimates 
β̃1 and β̃2, the average of the estimated standard error (SE), empirical standard deviation 
(SD), and coverage rate (%) of the nominal 95% confidence interval (CR). The subscripts 
for SE and SD refer to the proposed method (Pi) for disease i and the Kang et al. (2013) [6] 
method (Ki) for disease i. The simulation results suggest that both methods are 
approximately unbiased across the setup for β1 = β2 =0 and [β1, β2]=[0.1, 0.5]. The average 
of the proposed estimated standard error is close to the empirical standard deviation and it is 
in general smaller when subcohort size are larger, as expected. The 95% confidence interval 
coverage rate ranges between 94% and 97%. All the sample relative efficiencies (SREi), 
defined as  (i =1, 2), are larger than 1 which indicates that the proposed 
estimates are more efficient than those from Kang et al. [6]. This shows that the extra 
information collected on subjects with the other disease helps improve efficiency. In 
general, the efficiency gain is larger in situations with smaller subcohort size and smaller 
correlation.
We also compared the performance of our proposed estimator to Kang et al. [7]’s estimator 
in stratified case-cohort studies. To mimic the situation in the ARIC study with 1) CHD and 
stroke and 2) diabetes and hypertension, we consider two sets: 1) event proportion for 
disease 1 and disease 2 to be [3%,8%]according to the baseline hazard with 1 for disease 1 
and 4 for disease 2; 2) [11%,48%] according to the baseline hazard of 1 for disease 1 and 7 
for disease 2. We also set the case selection probabilities for disease 1 and disease 2 to be γ 
=[1, 1]and γ =[0.35, 0.35], respectively. Table 2 summarizes the results. All the sample 
relative efficiencies for β1 are greater than 1 which suggests that our proposed estimator for 
stratified case-cohort studies are more efficient than Kang et al. [6]’s estimators. The range 
of efficiency gain is 1% – 66%. However, efficiency gain for β2 is small. This is expected 
because there are not many additional disease cases in the case-cohort sample and therefore 
there are not much additional information for estimating β2. When the correlation between 
covariate and stratum variable is higher, sample standard deviation is smaller which 
indicates that more efficiency gain is associated with higher correlation between covariates 
and stratum variable.
Figure 1 shows standard errors of the full cohort, our proposed method, and Kang et al. [6] 
for the traditional and generalized case-cohort studies. The standard errors are obtained for 
the setup with the subcohort size ñ =100 and τθ =0.43. For generalized case-cohort studies, 
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we sampled half of the cases outside of the subcohort. Figure 1 shows that more efficiency 
gain compared to Kang et al. [6] is associated with higher event proportion.
5. Data Analysis
We applied the proposed methods to two data examples from the Atherosclerosis Risk in 
Communities (ARIC) study for illustration under the traditional and generalized case-cohort 
designs. The ARIC study is a longitudinal, population-based cohort study consisting of 
15,792 men and women aged from 45 to 64 years at baseline, recruited from four US 
communities. The first case-cohort study example is from the actual case-cohort studies in 
ARIC for rare diseases: incident coronary heart disease (CHD) event (7%) and stroke event 
(2%) [3]. To illustrate our methods for non-rare diseases, we constructed generalized case-
cohort sample for incident diabetes (11%) and incident hypertension (48%). Baseline 
measurements were obtained during 1987–1989 and follow up for incident coronary heart 
disease (CHD), stroke, diabetes, and hypertension events is through 1998. Incident CHD is 
defined as definite or probable myocardial infarction, electrocardiographic evidence of silent 
myocardial infarction, definite CHD death, or coronary revascularization procedure. 
Incident stroke is defined as a definite or probable ischemic stroke. Incident diabetes is 
defined as a reported physician diagnosis, use of antidiabetes medications, a fasting (≥ 8 
hours) glucose ≥ 7.0 mmol/l, or a nonfasting glucose of ≥ 11.1 mmol/l. Hypertension is 
defined as systolic blood pressure ≥ 140 or diastolic blood pressure ≥ 90 or used anti-
hypertensive medication in the previous two weeks. We regarded the subject as censored if 
he or she was free of that event type by December 31, 1998 or lost to follow-up during the 
study.
5.1. Example 1: the traditional case-cohort studies
The primary aim of the first study example was to investigate the association between 
PTGS1 polymorphisms and risk of incident CHD and stroke. Cyclooxygenase-derived 
prostaglandins can be significant modifiers of risk of cardiovascular disease events. It has 
been suggested that variation in the genes encoding cyclooxygenase-derived prostaglandins 
(PTGS1) play an important role in cardiovascular disease risk [13, 14, 15].
Using a case-cohort design, genomic DNA genotyped for the polymorphisms in PTGS1 was 
available on all incident CHD and ischemic stroke cases, and the subcohort. The subcohort 
was selected using a stratified sampling design with three stratifying variables: age (≥ 55 or 
< 55 years), gender, and race (Caucasian or African American). After excluding subjects 
with missing genotype data or covariates, the full cohort consisted of 13,731 subjects, which 
included 900 subjects with only CHD, 188 subjects with only stroke, and 61 subjects with 
both CHD and stroke. The subcohort contained 850 disease-free subjects, 72 subjects with 
only CHD, 15 subject with only stroke, and 7 subjects with both CHD and stoke. The total 
number with assayed samples was 1,999. To adjust for confounding and other risk factors, 
traditional and clinical covariates related to cardiovascular diseases were used: age, gender, 
race, study center, current smoking status, diabetes, and hypertension.
Figure 2 provides plots of the empirical cumulative hazard functions for CHD and stroke. 
For stroke events the difference in the cumulative hazard functions for the two genetic 
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variation groups appear to be increasing in an approximately linear fashion, while the two 
functions are not very different for CHD events. Based on these plots, the additive hazards 
model is appropriate for studying the effects of genetic variation (PTGS1) on CHD as well 
as on stroke. Since all cases for CHD and stoke were selected and we are interested in 
comparing the risk effects on CHD and on stroke, we conducted a simultaneous analysis by 
using the proposed method.
We initially fitted the model allowing for different effects for CHD and stroke and tested 
whether those effects are indeed different. If we cannot reject the null hypothesis that they 
are the same, we use common effect for that factor for CHD and stroke. Table 3 presents the 
results of the final model. After adjusting for age, gender, race, study center, current 
smoking status, diabetes, and hypertension, presence of at least one A allele was associated 
with significantly higher risk of stroke compared with homozygotes. We also fitted the same 
model using Kang et al. [6]’s method. In general, the standard errors for the proposed 
estimator are slightly smaller than those for the estimator of Kang et al. [6], which provide 
tighter confidence intervals for the estimated parameters.
5.2. Example 2: the generalized case-cohort studies
To illustrate our proposed approach and compare to the approach in Kang et al. [6] in 
generalized case-cohort studies with some common diseases, we constructed a generalized 
case-cohort sample from the ARIC study based on diabetes and hypertension. We used a 
subcohort size of 626 stratified by race. We then sampled 35% diabetes cases and 35% 
hypertension cases outside of the subcohort. The final generalized case-cohort sample has 
2267 subjects with 342 subjects having diabetes only, 1821 having hypertension only, and 
104 having both. We applied our proposed method to study the effect of total cholesterol, 
HDL cholesterol, smoking status, and body mass index (BMI) on the risk of diabetes and 
hypertension after adjusting for age, gender, race, and study center. We also fitted the same 
model using Kang et al. [6]’s method. Table 4 summarized the results. All the standard 
errors for the proposed estimator are smaller than those for the estimator of Kang et al. [6].
6. Concluding remarks
Using a new weight function, we have proposed more efficient estimators for the additive 
hazards model in a stratified case-cohort design with rare or non-rare diseases. The new 
weight functions incorporate the extra information for subjects with other diseases, which 
can help to increase efficiency relative to existing methods. However, under the situation 
that the disease rate is low, the proposed method did not improve efficiency much, because 
of the small amount of extra information. Moreover, we also showed that stratified sampling 
for the subcohort improved efficiency when the stratum variable is correlated with 
covariates.
We considered both traditional and generalized case-cohort studies in additive hazards 
models using unstratified sampling as well as stratified sampling. We applied Kim et al. 
[7]’s weight function for traditional case-cohort studies to additive hazards models. 
Moreover, we extend it to situation with non-rare diseases. Under the unstratified sampling, 
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our proposed estimators for both the traditional and generalized case-cohort designs are 
more efficient than those in Kang et al. [6].
It would be worthwhile to consider models with different associations between failure time 
and risk factors. We can adapt our approach to other types of models such as the 
proportional odds model, the accelerated failure time model, and the semiparametric 
transformation model by using all available information including stratum variables and 
covariate information for other diseases. These modifications are expected to improve 
efficiency.
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Figure 1. 
Comparison of standard errors
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Figure 2. 
Plots of Nelson-Aalen cumulative hazards function estimates for genetic variation
Kim et al. Page 14
Stat Med. Author manuscript; available in PMC 2017 January 30.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Kim et al. Page 15
Ta
bl
e 
1
Si
m
ul
at
io
n 
re
su
lt 
fo
r t
he
 u
ns
tra
tif
ie
d 
ca
se
-c
oh
or
t s
tu
dy
[β 1
, 
β 2
]
Ev
en
t P
ro
po
rt
io
n
ñ
τ θ
Pr
op
os
ed
 m
et
ho
d
K
an
g 
et
 a
l.’
s m
et
ho
d
SR
E 1
Pr
op
os
ed
 m
et
ho
d
K
an
g 
et
 a
l.’
s m
et
ho
d
SR
E 2
β̃ 1
SE
p1
SD
p1
CR
β̂ 1
SE
k1
SD
k1
CR
β̃ 2
SE
p2
SD
p2
CR
β̂ 2
SE
k2
SD
k2
CR
[0
, 0
]
[5
%
, 9
%
]
γ=
 [1
, 1
]
10
0
0.
83
−
0.
02
0.
73
0.
75
0.
94
−
0.
02
0.
75
0.
76
0.
95
1.
03
−
0.
07
1.
23
1.
25
0.
96
−
0.
07
1.
24
1.
25
0.
96
1.
01
0.
43
0.
00
0.
73
0.
73
0.
95
0.
00
0.
74
0.
74
0.
95
1.
04
−
0.
01
1.
22
1.
22
0.
96
0.
00
1.
24
1.
23
0.
96
1.
03
0.
11
0.
03
0.
72
0.
70
0.
96
0.
03
0.
74
0.
72
0.
96
1.
05
0.
00
1.
22
1.
24
0.
96
0.
00
1.
24
1.
26
0.
96
1.
03
0
0.
02
0.
73
0.
73
0.
95
0.
03
0.
74
0.
75
0.
96
1.
05
0.
00
1.
22
1.
23
0.
96
−
0.
01
1.
23
1.
25
0.
96
1.
02
20
0
0.
83
−
0.
01
0.
64
0.
63
0.
95
−
0.
01
0.
65
0.
64
0.
95
1.
02
−
0.
02
1.
01
1.
01
0.
96
−
0.
02
1.
02
1.
02
0.
96
1.
00
0.
43
0.
02
0.
64
0.
64
0.
95
0.
02
0.
65
0.
65
0.
95
1.
02
−
0.
01
1.
01
1.
01
0.
95
−
0.
02
1.
02
1.
02
0.
95
1.
02
0.
11
0.
01
0.
64
0.
63
0.
95
0.
02
0.
65
0.
64
0.
95
1.
02
0.
01
1.
01
0.
96
0.
96
0.
01
1.
02
0.
97
0.
96
1.
02
0
0.
00
0.
64
0.
64
0.
95
0.
00
0.
65
0.
64
0.
95
1.
02
0.
01
1.
00
1.
01
0.
96
0.
01
1.
01
1.
02
0.
96
1.
02
[1
5%
, 2
6%
]
γ=
 [0
.5,
 0.
5]
10
0
0.
83
0.
00
0.
57
0.
58
0.
96
0.
00
0.
63
0.
65
0.
96
1.
27
0.
00
1.
05
1.
05
0.
96
0.
00
1.
08
1.
09
0.
96
1.
07
0.
43
−
0.
02
0.
57
0.
58
0.
95
−
0.
01
0.
63
0.
64
0.
96
1.
20
−
0.
02
1.
03
1.
06
0.
96
−
0.
03
1.
08
1.
09
0.
96
1.
07
0.
11
−
0.
01
0.
56
0.
57
0.
95
−
0.
01
0.
62
0.
62
0.
97
1.
17
−
0.
03
1.
02
1.
05
0.
95
−
0.
04
1.
08
1.
12
0.
95
1.
14
0
0.
00
0.
56
0.
59
0.
96
0.
01
0.
62
0.
65
0.
96
1.
21
−
0.
02
1.
01
1.
05
0.
95
−
0.
01
1.
07
1.
12
0.
95
1.
13
20
0
0.
83
0.
00
0.
47
0.
47
0.
96
0.
00
0.
51
0.
52
0.
96
1.
20
−
0.
03
0.
81
0.
81
0.
95
−
0.
03
0.
83
0.
84
0.
96
1.
07
0.
43
0.
00
0.
47
0.
49
0.
94
0.
01
0.
51
0.
53
0.
95
1.
16
−
0.
01
0.
80
0.
82
0.
95
−
0.
01
0.
83
0.
85
0.
96
1.
07
0.
11
0.
00
0.
48
0.
48
0.
95
−
0.
02
0.
51
0.
51
0.
96
1.
14
−
0.
03
0.
80
0.
81
0.
95
−
0.
03
0.
83
0.
84
0.
95
1.
08
0
0.
00
0.
48
0.
49
0.
95
0.
00
0.
51
0.
52
0.
95
1.
14
0.
00
0.
80
0.
83
0.
95
0.
00
0.
83
0.
86
0.
95
1.
07
[0
.1,
 0.
5]
[5
%
, 9
%
]
γ=
 [1
, 1
]
10
0
0.
83
0.
10
0.
75
0.
74
0.
95
0.
11
0.
76
0.
75
0.
95
1.
02
0.
49
1.
29
1.
31
0.
96
0.
49
1.
30
1.
32
0.
96
1.
01
0.
43
0.
13
0.
74
0.
77
0.
93
0.
13
0.
76
0.
78
0.
94
1.
02
0.
55
1.
29
1.
26
0.
96
0.
55
1.
30
1.
28
0.
97
1.
02
0.
11
0.
11
0.
74
0.
75
0.
95
0.
12
0.
76
0.
77
0.
95
1.
06
0.
49
1.
29
1.
27
0.
96
0.
49
1.
31
1.
30
0.
96
1.
04
0
0.
13
0.
74
0.
75
0.
96
0.
13
0.
76
0.
77
0.
96
1.
05
0.
54
1.
28
1.
32
0.
96
0.
54
1.
30
1.
34
0.
96
1.
03
20
0
0.
83
0.
11
0.
66
0.
64
0.
96
0.
11
0.
66
0.
65
0.
96
1.
01
0.
49
1.
07
1.
07
0.
96
0.
50
1.
07
1.
07
0.
96
1.
00
0.
43
0.
09
0.
66
0.
66
0.
95
0.
09
0.
66
0.
67
0.
95
1.
02
0.
54
1.
06
1.
07
0.
94
0.
54
1.
07
1.
08
0.
95
1.
01
0.
11
0.
10
0.
65
0.
66
0.
95
0.
09
0.
66
0.
66
0.
95
1.
02
0.
48
1.
05
1.
07
0.
95
0.
48
1.
06
1.
08
0.
95
1.
03
0
0.
11
0.
65
0.
66
0.
95
0.
11
0.
66
0.
66
0.
95
1.
01
0.
52
1.
05
1.
06
0.
95
0.
52
1.
06
1.
07
0.
95
1.
03
[1
5%
, 2
6%
]
γ=
 [0
.5,
 0.
5]
10
0
0.
83
0.
12
0.
58
0.
59
0.
96
0.
11
0.
64
0.
66
0.
96
1.
23
0.
52
1.
11
1.
17
0.
95
0.
52
1.
14
1.
20
0.
95
1.
05
0.
43
0.
10
0.
58
0.
59
0.
96
0.
10
0.
64
0.
66
0.
96
1.
25
0.
51
1.
09
1.
10
0.
95
0.
51
1.
13
1.
15
0.
96
1.
09
0.
11
0.
10
0.
58
0.
61
0.
95
0.
10
0.
64
0.
66
0.
95
1.
20
0.
51
1.
07
1.
08
0.
96
0.
53
1.
13
1.
13
0.
96
1.
10
Stat Med. Author manuscript; available in PMC 2017 January 30.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Kim et al. Page 16
[β 1
, 
β 2
]
Ev
en
t P
ro
po
rt
io
n
ñ
τ θ
Pr
op
os
ed
 m
et
ho
d
K
an
g 
et
 a
l.’
s m
et
ho
d
SR
E 1
Pr
op
os
ed
 m
et
ho
d
K
an
g 
et
 a
l.’
s m
et
ho
d
SR
E 2
β̃ 1
SE
p1
SD
p1
CR
β 1̂
SE
k1
SD
k1
CR
β̃ 2
SE
p2
SD
p2
CR
β̂ 2
SE
k2
SD
k2
CR
0
0.
08
0.
58
0.
60
0.
95
0.
08
0.
64
0.
67
0.
95
1.
28
0.
50
1.
06
1.
08
0.
96
0.
49
1.
13
1.
15
0.
97
1.
14
20
0
0.
83
0.
09
0.
48
0.
49
0.
95
0.
09
0.
53
0.
54
0.
94
1.
22
0.
52
0.
85
0.
86
0.
96
0.
52
0.
88
0.
89
0.
95
1.
07
0.
43
0.
11
0.
48
0.
50
0.
95
0.
11
0.
53
0.
54
0.
95
1.
17
0.
49
0.
85
0.
84
0.
96
0.
49
0.
88
0.
88
0.
96
1.
08
0.
11
0.
11
0.
49
0.
49
0.
96
0.
11
0.
53
0.
52
0.
96
1.
14
0.
50
0.
84
0.
88
0.
95
0.
50
0.
88
0.
93
0.
95
1.
10
0
0.
10
0.
49
0.
50
0.
95
0.
10
0.
52
0.
53
0.
95
1.
13
0.
48
0.
84
0.
86
0.
95
0.
48
0.
88
0.
89
0.
95
1.
08
SE
i, 
th
e 
av
er
ag
e 
of
 th
e 
es
tim
at
es
 o
f s
ta
nd
ar
d 
er
ro
r f
or
 β i
; S
D
i, 
sa
m
pl
e 
sta
nd
ar
d 
de
vi
at
io
n 
fo
r β
i; 
CR
, t
he
 c
ov
er
ag
e 
ra
te
 o
f t
he
 n
om
in
al
 9
5%
 co
nf
id
en
ce
 in
te
rv
al
s; 
,
 
sa
m
pl
e 
re
la
tiv
e 
ef
fic
ie
nc
y
Stat Med. Author manuscript; available in PMC 2017 January 30.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Kim et al. Page 17
Ta
bl
e 
2
Si
m
ul
at
io
n 
re
su
lt 
fo
r c
om
pa
ris
on
 o
f t
w
o 
m
et
ho
ds
 in
 st
ra
tif
ie
d 
ca
se
-c
oh
or
t s
tu
dy
 [β
1,
 
β 2
] =
 [0
.1,
 0]
Ev
en
t P
ro
po
rt
io
n
[ν
, 
η]
τ θ
Pr
op
os
ed
 m
et
ho
d
K
an
g 
et
 a
l.’
s m
et
ho
d
SR
E 1
Pr
op
os
ed
 m
et
ho
d
K
an
g 
et
 a
l.’
s m
et
ho
d
SR
E 2
β̃ 1
SE
p1
SD
p1
CR
β̂ 1
SE
k1
SD
k1
CR
β̃ 2
SE
p2
SD
p2
CR
β̂ 2
SE
k2
SD
k2
CR
[3
%
, 8
%
]
γ=
 [1
, 1
]
[0
.5,
 0.
5]
0.
83
0.
12
0.
45
0.
47
0.
92
0.
12
0.
46
0.
47
0.
93
1.
02
0.
00
1.
18
1.
21
0.
96
−
0.
01
1.
19
1.
21
0.
96
1.
00
0.
43
0.
09
0.
44
0.
45
0.
93
0.
09
0.
46
0.
46
0.
93
1.
04
−
0.
03
1.
18
1.
20
0.
95
−
0.
03
1.
19
1.
20
0.
95
1.
01
0.
11
0.
12
0.
45
0.
46
0.
92
0.
12
0.
46
0.
47
0.
92
1.
04
0.
01
1.
17
1.
17
0.
96
0.
01
1.
19
1.
18
0.
96
1.
02
0
0.
10
0.
45
0.
45
0.
93
0.
10
0.
46
0.
46
0.
93
1.
04
0.
00
1.
17
1.
19
0.
96
0.
00
1.
19
1.
21
0.
96
1.
03
[0
.7,
 0.
7]
0.
83
0.
11
0.
44
0.
44
0.
92
0.
11
0.
45
0.
45
0.
93
1.
03
−
0.
04
1.
14
1.
14
0.
96
−
0.
04
1.
15
1.
14
0.
96
1.
00
0.
43
0.
10
0.
44
0.
45
0.
93
0.
10
0.
45
0.
45
0.
93
1.
03
0.
03
1.
13
1.
13
0.
96
0.
02
1.
15
1.
13
0.
96
1.
02
0.
11
0.
11
0.
44
0.
46
0.
92
0.
11
0.
45
0.
47
0.
92
1.
03
0.
02
1.
13
1.
14
0.
95
0.
02
1.
14
1.
15
0.
96
1.
01
0
0.
09
0.
44
0.
44
0.
93
0.
09
0.
45
0.
44
0.
93
1.
01
−
0.
02
1.
12
1.
12
0.
96
−
0.
02
1.
14
1.
12
0.
96
1.
02
[1
1%
, 5
0%
]
γ=
 [0
.35
, 0
.35
]
[0
.5,
 0.
5]
0.
83
0.
10
0.
31
0.
32
0.
96
0.
09
0.
40
0.
40
0.
96
1.
60
0.
00
1.
67
1.
70
0.
95
0.
01
1.
68
1.
72
0.
95
1.
02
0.
43
0.
11
0.
33
0.
33
0.
95
0.
12
0.
40
0.
40
0.
96
1.
44
0.
05
1.
67
1.
71
0.
95
0.
05
1.
68
1.
72
0.
95
1.
01
0.
11
0.
11
0.
35
0.
34
0.
95
0.
11
0.
40
0.
40
0.
96
1.
41
−
0.
03
1.
64
1.
67
0.
94
0.
01
1.
69
1.
73
0.
95
1.
06
0
0.
11
0.
34
0.
34
0.
96
0.
10
0.
40
0.
40
0.
95
1.
42
0.
00
1.
62
1.
63
0.
95
−
0.
02
1.
68
1.
70
0.
95
1.
08
[0
.7,
 0.
7]
0.
83
0.
10
0.
31
0.
29
0.
97
0.
10
0.
40
0.
38
0.
97
1.
66
0.
01
1.
67
1.
55
0.
97
0.
01
1.
68
1.
56
0.
97
1.
02
0.
43
0.
11
0.
33
0.
32
0.
97
0.
11
0.
40
0.
39
0.
96
1.
43
0.
06
1.
70
1.
59
0.
97
0.
06
1.
68
1.
62
0.
97
1.
03
0.
11
0.
11
0.
34
0.
34
0.
95
0.
11
0.
40
0.
40
0.
95
1.
42
0.
00
1.
64
1.
62
0.
96
−
0.
02
1.
67
1.
65
0.
96
1.
05
0
0.
11
0.
34
0.
32
0.
97
0.
11
0.
40
0.
37
0.
97
1.
35
0.
00
1.
63
1.
57
0.
96
0.
00
1.
68
1.
61
0.
96
1.
05
SE
i, 
th
e 
av
er
ag
e 
of
 th
e 
es
tim
at
es
 o
f s
ta
nd
ar
d 
er
ro
r f
or
 β i
; S
D
i, 
sa
m
pl
e 
sta
nd
ar
d 
de
vi
at
io
n 
fo
r β
i; 
CR
, t
he
 c
ov
er
ag
e 
ra
te
 o
f t
he
 n
om
in
al
 9
5%
 co
nf
id
en
ce
 in
te
rv
al
s; 
,
 
sa
m
pl
e 
re
la
tiv
e 
ef
fic
ie
nc
y
Stat Med. Author manuscript; available in PMC 2017 January 30.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Kim et al. Page 18
Ta
bl
e 
3
A
na
ly
sis
 re
su
lts
 fo
r t
he
 e
ffe
ct
s o
f P
TG
S1
 G
/A
+A
/A
 v
er
su
s G
/G
 (×
10
−
6 )
V
ar
ia
bl
e
Pr
op
os
ed
 m
et
ho
d
K
an
g 
et
 a
l’s
 m
et
ho
d
β̃
SE
P-
va
lu
e
β̂
SE
P-
va
lu
e
CH
D
PT
G
S1
2.
44
2.
92
7
0.
20
2
2.
38
2.
93
0
0.
20
8
A
ge
0.
69
0.
18
0
<
 0
.0
01
0.
69
0.
18
2
<
 0
.0
01
M
al
e
20
.0
9
2.
14
0
<
 0
.0
01
19
.9
1
2.
15
6
<
 0
.0
01
Ce
nt
er
 (F
)
−
2.
04
3.
29
7
0.
26
8
−
2.
25
3.
30
5
0.
24
8
Ce
nt
er
 (J
)
−
8.
08
5.
25
5
0.
06
2
−
8.
71
5.
29
6
0.
05
0
Ce
nt
er
 (M
)
−
9.
08
3.
02
5
0.
00
1
−
9.
03
3.
04
6
0.
00
2
Cu
rre
nt
 sm
ok
in
g
12
.7
7
2.
58
2
<
 0
.0
01
12
.7
5
2.
61
3
<
 0
.0
01
D
ia
be
te
s
22
.4
5
5.
30
6
<
 0
.0
01
23
.0
4
5.
44
1
<
 0
.0
01
H
yp
er
te
ns
io
n
15
.2
4
2.
73
0
<
 0
.0
01
15
.3
7
2.
75
7
<
 0
.0
01
St
ro
ke
PT
G
S1
2.
85
1.
47
0
0.
02
6
3.
01
1.
52
9
0.
02
4
A
ge
0.
33
0.
07
3
<
 0
.0
01
0.
33
0.
07
5
<
 0
.0
01
M
al
e
2.
36
0.
80
0
0.
00
2
2.
30
0.
81
5
0.
00
2
Ce
nt
er
 (F
)
0.
22
1.
16
0
0.
42
4
0.
17
1.
21
6
0.
44
3
Ce
nt
er
 (J
)
6.
63
4.
39
8
0.
06
6
6.
03
4.
43
5
0.
08
7
Ce
nt
er
 (M
)
−
0.
45
0.
97
0
0.
32
2
−
0.
76
0.
98
6
0.
22
2
Cu
rre
nt
 sm
ok
in
g
4.
09
1.
04
5
<
 0
.0
01
4.
38
1.
08
9
<
 0
.0
01
D
ia
be
te
s
9.
52
2.
32
7
<
 0
.0
01
8.
65
2.
26
6
<
 0
.0
01
H
yp
er
te
ns
io
n
6.
20
1.
10
2
<
 0
.0
01
6.
05
1.
12
4
<
 0
.0
01
Co
m
m
on
 e
ffe
ct
A
fri
ca
n
−
4.
74
4.
21
8
0.
13
1
−
4.
30
4.
23
4
0.
15
5
Stat Med. Author manuscript; available in PMC 2017 January 30.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Kim et al. Page 19
Ta
bl
e 
4
A
na
ly
sis
 re
su
lts
 fo
r D
ia
be
te
s a
nd
 H
yp
er
te
ns
io
n 
(×
10
−
5 )
V
ar
ia
bl
e
Pr
op
os
ed
 m
et
ho
d
K
an
g 
et
 a
l’s
 m
et
ho
d
β̃
SE
P-
va
lu
e
β̂
SE
P-
va
lu
e
D
ia
be
te
s
B
M
I
0.
50
2
0.
05
4
<
 0
.0
01
0.
57
2
0.
09
5
<
 0
.0
01
Cu
rre
nt
 sm
ok
in
g
−
0.
30
0
0.
45
3
0.
25
4
−
0.
15
4
0.
64
1
0.
40
5
H
yp
er
te
ns
io
n
B
M
I
0.
08
7
0.
03
4
0.
00
5
0.
13
8
0.
05
5
0.
00
6
Cu
rre
nt
 sm
ok
in
g
2.
95
7
0.
53
1
<
 0
.0
01
3.
06
0
0.
73
6
<
 0
.0
01
Co
m
m
on
 e
ffe
ct
A
ge
−
0.
09
0
0.
01
1
<
 0
.0
01
−
0.
08
2
0.
01
7
<
 0
.0
01
A
fri
ca
n
0.
00
4
0.
00
5
0.
19
8
0.
01
5
0.
00
8
0.
03
2
H
D
L 
Ch
ol
es
te
ro
l
1.
10
4
0.
18
8
<
 0
.0
01
1.
04
4
0.
25
7
<
 0
.0
01
To
ta
l C
ho
le
ste
ro
l
−
1.
69
0
1.
79
3
0.
17
3
−
1.
47
3
2.
08
6
0.
24
0
M
al
e
1.
38
3
0.
17
1
<
 0
.0
01
1.
36
2
0.
19
7
<
 0
.0
01
Ce
nt
er
 (F
)
17
.3
44
2.
31
1
<
 0
.0
01
17
.4
38
2.
54
6
<
 0
.0
01
Ce
nt
er
 (J
)
−
0.
12
6
0.
04
8
0.
00
4
−
0.
11
6
0.
05
2
0.
01
3
Ce
nt
er
 (M
)
0.
02
3
0.
02
4
0.
17
2
0.
01
9
0.
02
6
0.
23
2
Stat Med. Author manuscript; available in PMC 2017 January 30.
